Summary
The episode works through why the psilocybin trials in alcohol use disorder conflict, what a small trial with a null result can show, and how wide the uncertainty is around the largest trial's reduction in heavy drinking days. Sarah and Kiffer test the fragility of the smoking pilot trial's odds ratio with a hypothetical change of four participants, and then compare deaths around ibogaine treatment with excess deaths after leaving methadone in a hypothetical group built from a 2026 preprint and a 2017 review of cohort studies. The hosts examine what the 2013 retreat study in a First Nations community in British Columbia and the evaluations of Roots to Thrive among health care workers can support, with attention to principles that an Indigenous-led group proposed for psychedelic research. They close by debating whether psychedelic addiction trials should attempt to blind participants or use open designs with biological checks.